Clearstead Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Clearstead Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-82	Closed	–	–	1317
2022 Q3	$0	Hold	82	–	–	﹤0.01%	1254
2022 Q2	$0	Hold	82	–	–	﹤0.01%	1282
2022 Q1	$0	Hold	82	–	–	﹤0.01%	1375
2021 Q4	$0	Hold	82	–	–	﹤0.01%	1284
2021 Q3	$1K	Hold	82	–	–	﹤0.01%	1179
2021 Q2	$1K	Buy	+82	New	+$1.62K	﹤0.01%	1123

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Clearstead Advisors's BDTX Position: Q4 2022 in Review

Clearstead Advisors sold out of Black Diamond Therapeutics (BDTX) in Q4 2022, closing a stake of 82 shares.

Clearstead Advisors first reported a position in BDTX in Q2 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2021. 59 funds tracked by Wall St. Rank hold BDTX as of Q4 2022.

Clearstead Advisors reported no remaining Black Diamond Therapeutics position as of Q4 2022 after selling out during the quarter.
Clearstead Advisors sold 82 Black Diamond Therapeutics shares in Q4 2022.
Clearstead Advisors first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 6 quarters.
Clearstead Advisors's Black Diamond Therapeutics position peaked at $1K in Q3 2021.
59 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2022.

Based on Clearstead Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.